

**UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF LOUISIANA**

In re Actos (Pioglitazone) Product
Liability Litigation

*
*
*
*
*
*
*

6:11-md-2299

This Document Applies to:

JUDGE DOHERTY
MAGISTRATE JUDGE HANNA

All Cases

**MONTHLY REPORT ON NOTICES OF ELECTRONIC FILING
OCTOBER 14, 2013 TO NOVEMBER 14, 2013**

File Date	Date Served	Document Number	Description of Pleading	Distribution List
10/14/2013	10/15/2013	3399; 19	ANSWER to Plaintiff's Complaint with Jury Demand – Ciminera v. Takeda Pharmaceuticals America Inc et al	All
10/14/2013	10/15/2013	3400; 23	ANSWER to Plaintiff's Complaint with Jury Demand – Johnson v. Takeda Pharmaceutical Co. Ltd, et al.	All
10/14/2013	10/15/2013	3401, 64	ANSWER to Plaintiff's Complaint with Jury Demand – Kibler v. Takeda Pharmaceuticals U S A Inc et al	All
10/14/2013	10/15/2013	3402; 80	PROOF OF SERVICE of Summons and Complaint – Quillen et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/14/2013	10/15/2013	3404; 269	MOTION in Limine <i>Defendants' Motion in Limine to Exclude Evidence and Argument regarding Takeda or Eli Lilly Drugs Withdrawn from the Market –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3403; 268	MOTION in Limine <i>Defendants' Motion in Limine to Exclude Certain Evidence and Argument regarding Adverse Event Reports –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All

10/14/2013	10/15/2013	3405; 270	MOTION in Limine <i>Defendants' Motion in Limine to Exclude Evidence of Foreign Marketing and Sales Materials-</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3406; 271	MOTION in Limine <i>Defendants' Motion in Limine to Exclude Evidence and Argument regarding Foreign Regulatory Activities –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3408; 273	MOTION in Limine <i>Defendants' Motion in Limine to Exclude the Testimony of Helen Ge –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3409; 274	MOTION in Limine <i>Defendants' Motion in Limine to Exclude Evidence and Argument Regarding Takeda Chemical Industries Ltd.'s Vitamins Plea –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3410; 275	MOTION for Leave to File Excess Pages <i>Defendants' Motion to Exceed Page Limit from 25 to 35 pages for a Memorandum in Support of Motion for Partial Summary Judgment on all Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3411; 276	MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption)</i> Modified on 10/15/2013 to properly link to exhibits; Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3412; 277	MOTION in Limine <i>to Exclude as Irrelevant and Prejudicial any Evidence or Reference Concerning Rare Fatal Side-Effects of Commonly Used Over-The-Counter (OTC) Drugs by PSC. –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3413; 278	EXHIBIT 1-21 to <i>Defendants' Motion for Partial Summary Judgment on all Claims for Relief and Allegations based</i>	All

			<i>upon Failure to Warn (Federal Preemption) –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	
10/14/2013	10/15/2013	3414; 279	MOTION in Limine <i>to Exclude Any Reference to Payments Made to Plaintiff Allens Treating Doctor for his Time During Deposition, Preparation, and for his Review of Medical Literature</i> by PSC. – Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3415; 280	SEALED MOTION <i>Defendants' Motion for Summary Judgment</i> - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3416; 281	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibits 22-40</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3417; 282	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibits 41 - 53</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3418; 283	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibits 54 – 66</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3419; 284	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibits 67-69</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All

10/14/2013	10/15/2013	3420; 285	MOTION in Limine to Exclude Any Reference to Product Labeling and Other Evidence of Pharmaceutical Drugs Taken by Plaintiff Other than Actos by PSC. – Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3421; 286	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibits 70-77-</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3422; 287	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibits 78-79</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3423; 288	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibit 80 (part 1 of 2)</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3424; 289	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibit 80 (part 2 of 2)</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3425; 290	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibits 81 - 84 (part 1 of 2)</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3426; 291	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and</i>	All

			<i>Allegations Based Upon Failure to Warn (Federal Preemption) Exhibit 84 (part 2 of 2)</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	
10/14/2013	10/15/2013	3427; 292	EXHIBIT re (3411 in 6:11-md-02299-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption) Exhibit 85 –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3428; 293	MOTION in Limine <i>to Exclude Any Evidence That Pioglitazone is Beneficial to or Decreases the Risk of Certain Types of Cancer</i> by PSC – Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/14/2013	10/15/2013	3429; 294	MOTION in Limine <i>to Exclude any Evidence or Discussion of Defendants Role as Innovators of the TZD Class and the Pioglitazone Compound</i> by PSC – Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/15/2013	10/15/2013	3430; 295	MOTION in Limine <i>to Exclude Evidence or Testimony to the July/August 2013 AACE/ACE Diabetes and Cancer Consensus Statement</i> by PSC – Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/15/2013	10/15/2013	3431; 60	AMENDED COMPLAINT - Cruz et al v. Takeda Pharmaceuticals America Inc et al	All
10/15/2013	10/15/2013	3432; 14	PROOF OF SERVICE of Summons & Complaint- Rosenblum v. Takeda Pharmaceuticals America Inc et al	All
10/15/2013	10/15/2013	3433; 15	PROOF OF SERVICE of Summons & Complaint- Rosenblum v. Takeda Pharmaceuticals America Inc et al	All
10/15/2013	10/15/2013	3434; 54	PROOF OF SERVICE <i>on Defendants –</i> Horner et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/16/2013	10/16/2013	3435; 6	NOTICE by Clyde Hardesty, Jean Hardesty of Certificate of Good Standing Associated Cases: 6:11-md-02299-RFD-	All

			PJH, 6:13-cv-02760-RFD-PJH(aty,Price, Robert) - Hardesty v. Takeda Pharmaceuticals America Inc et al	
10/16/2013	10/16/2013	3436; 126	ANSWER to Plaintiff's Complaint with Jury Demand; Person v. Takeda Pharmaceuticals America Inc et al	All
10/16/2013	10/16/2013	3437; 47; 47; 47; 47; 47	PROOF OF SERVICE of Summons, Bundled Complaint with Jury Demand and Severance Order - Canales et al v. Takeda Pharmaceuticals America Inc et al; Nellist et al v. Takeda Pharmaceuticals America Inc et al; Orcutt et al v. Takeda Pharmaceuticals America Inc et al; Terilla et al v. Takeda Pharmaceuticals America Inc et al; Young et al v. Takeda Pharmaceuticals America Inc et al	All
10/16/2013	10/16/2013	3438; 296	MOTION in Limine <i>Defendants' Motion in Limine to Exclude Evidence or Argument Regarding the Attendance or Non-Attendance of Certain Witnesses at Trial-</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/15/2013	10/16/2013	3439; 297	MINUTES for proceedings held before Judge Rebecca F Doherty: STATUS CONFERENCE and ORAL ARGUMENT ON MOTIONS held on 10/15/2013. Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/4/2013	10/16/2013	No Document no.; No Document no.	Motions Transferred regarding (3410 in 6:11-md-02299-RFD-PJH, 275 in 6:12-cv-00064-RFD-PJH) MOTION for Leave to File Excess Pages <i>Defendants' Motion to Exceed Page Limit from 25 to 35 pages for a Memorandum in Support of Motion for Partial Summary Judgment on all Claims for Relief and Allegations Based Upon Failure to Warn and (280 in 6:12-cv-00064-RFD-PJH, 3415 in 6:11-md-02299-RFD-PJH) SEALED MOTION Defendants' Motion for Summary Judgment. Motions referred to Judge Rebecca F Doherty.-</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/15/2013	10/17/2013	3441; 140	MAIL RETURNED as Undeliverable: Mail sent to James P Gregory, 1370 5th Ave Apt D, Manhattan, NY 10026, - Gregory v. Takeda Pharmaceuticals America Inc et al	All

10/15/2013	10/17/2013	3442; 141	MAIL RETURNED as Undeliverable: Mail sent to James P Gregory, 1370 5th Ave Apt D, Manhattan, NY 10026, - Gregory v. Takeda Pharmaceuticals America Inc et al	All
10/17/2013	10/17/2013	3443, 142	NOTICE of Manual Attachment re (3415 in 6:11-md-02299-RFD-PJH) SEALED MOTION <i>Defendants' Motion for Summary Judgment Exhibits 12a – 15-</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/18/2013	10/18/2013	No document attached; No document attached	MANUAL ATTACHMENT regarding (280 in 6:12-cv-00064-RFD-PJH, 3415 in 6:11-md-02299-RFD-PJH) SEALED MOTION <i>Defendants' Motion for Summary Judgment</i> . The original manual attachments will be maintained in the division of the presiding judge, until expiration of appeal delays. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/11/2013	10/17/2013	3444 (Spread to all cases)	NOTICE of Service List pursuant to (3398 in 6:11-md-02299-RFD-PJH) Case Management Order, filed by Plaintiff's Liasion Counsel.	All
10/16/2013	10/17/2013	3445	REPORT AND RECOMMENDATIONS ON REQUEST FOR DISTRIBUTION OF FUNDS. In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/18/2013	10/18/2013	3446	ORDER ADOPTING [3347] Report and Recommendation for Distribution of Funds. - In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/18/2013	10/18/2013	3447; 35	ANSWER to Plaintiff's Complaint with Jury Demand. Ali v. Takeda Pharmaceuticals U S A Inc et al	All
10/18/2013	10/18/2013	3448; 60	ANSWER to Plaintiff's Complaint with Jury Demand. Olsen v. Takeda Pharmaceuticals U S A Inc et al	All
10/3/2013	10/18/2013	3449; 17;	CONDITIONAL TRANSFER ORDER (CTO-60) by the Judicial Panel on Multidistrict Litigation - Templet et al v. Takeda Pharmaceuticals America Inc et al;	All

		18; 19; 21	Dunard v. Takeda Pharmaceutical Co Ltd et al Davis v. Takeda Pharmaceutical Co Ltd et al Stewart et al v. Takeda Pharmaceutical Co Ltd et al	
10/18/2013	10/18/2013	3450 (Spread to all cases)	STIPULATED PROTECTIVE ORDER Regarding Takeda Defendants' Access To Non-Parties Kaiser Foundation Hospitals, The Permanente Medical Group, Inc And Kaiser Foundation Health Plan Inc's Analytical Files And Other Highly Confidential Information.- In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/20/2013	10/20/2013	3451; 47; 47; 47; 47; 47; 47; 47; 47; 47; 47	ANSWER to Multi-plaintiff Complaint with Jury Demand. Cunningham v. Takeda Pharmaceuticals U S A Inc et al; McCormick v. Takeda Pharmaceuticals U S A Inc et al; Paniccia v. Takeda Pharmaceuticals U S A Inc et al; Wycoff v. Takeda Pharmaceuticals U S A Inc et al; Cavalo et al v. Takeda Pharmaceuticals U S A Inc et al; Fernandes et al v. Takeda Pharmaceuticals U S A Inc et al; Guglielmo et al v. Takeda Pharmaceuticals U S A Inc et al; Henderson v. Takeda Pharmaceuticals U S A Inc et al; Wall et al v. Takeda Pharmaceuticals U S A Inc et al; Way et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/20/2013	10/20/2013	3452; 149; 149; 149; 149; 149; 149; 149; 149; 149;	ANSWER to Plaintiffs' Amended Complaint with Jury Demand. Blake v. Takeda Pharmaceuticals America Inc et al; Cavalier v. Takeda Pharmaceuticals America Inc et al; Duncan v. Takeda Pharmaceuticals America Inc et al; Kopp v. Takeda Pharmaceuticals America Inc et al; Miller v. Takeda Pharmaceuticals America Inc et al; Myers v. Takeda Pharmaceuticals America Inc et al; Pryor v. Takeda Pharmaceuticals America Inc et al; Whitfield v. Takeda Pharmaceuticals America Inc et al;	All

		89	Young v. Takeda Pharmaceuticals America Inc et al	
10/21/2013	10/21/2013	3453; 82	PROOF OF SERVICE of Proof of Service of Summons and Complaint- Tantillo et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/21/2013	10/21/2013	3454; 98	PROOF OF SERVICE of Proof of Service of Summons and Complaint- Tomeck v. Takeda Pharmaceuticals U S A Inc et al	All
10/21/2013	10/21/2013	3455; 86	PROOF OF SERVICE of Proof of Service of Summons and Complaint- Garner et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/21/2013	10/21/2013	3456; 302	MOTION for Leave to File Sealed Motion In Limine with consent by PSC. (Attachments: # (1) Proposed order) – Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3457; 303	SEALED MOTION <i>Plaintiffs Motion in Limine to Exclude any Evidence or Discussion of the General Cardiovascular Risks of Type 2 Diabetes and Related Statistics while and also Claiming, Implying or Suggesting that Actos Reduces Such Risk in the Same Population</i> by PSC. (Attachments: # (1) Memorandum / Brief, # (2) Exhibit A-F, # (3) Proposed order) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/16/2013	10/21/2013	3458; 15	CONDITIONAL TRANSFER ORDER (CTO-61) by the Judicial Panel on Multi-district Litigation - Kincaid v. Eli Lilly & Co et al	All
10/21/2013	10/21/2013	3459; 304	NOTICE OF FILING OF OFFICIAL TRANSCRIPT of Proceedings filed for ORAL ARGUMENT ON MOTIONS IN LIMINE held on 10/15/2013 before Judge Rebecca F. Doherty. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3460; 105	PROOF OF SERVICE of Proof of Service of Summons and Complaint - Payne et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3461 (Spread	MOTION for Leave to File Excess Pages by PSC .-	All

		to all cases)	In Re: Actos (Pioglitazone) Products Liability Litigation	
10/21/2013	10/21/2013	3462; 306	DAUBERT MOTION <i>Defendants' Memorandum of Law Applicable to the Admissibility of Certain Expert Testimony-</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3463; 307	SEALED DOCUMENT: Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dr. Scott Delacroix re (3462 in 6:11-md-02299-RFD-PJH) DAUBERT MOTION <i>Defendants' Memorandum of Law Applicable to the Admissibility of Certain Expert Testimony. -</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3464; 308	Second DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Sebastian Schneeweiss -</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3465; 309	Third DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Herbert Barton Grossman, M.D. -</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3466; 310	Fourth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Experts That Actos Can Cause Bladder Cancer Within One Year of Use –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3467; 311	Fifth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dipak Panigraphy, M.D. –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3468; 312	Sixth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Jennifer Southgate, Ph.D. . –</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3469; 313	SEALED DOCUMENT: Defendants' Motion to Exclude Testimony of Plaintiffs' Experts David Altman, M.D., Dan Bagwell, R.N., and Kristin Kucsma, M.A., Regarding	All

			"Outcome Scenario II" - Allen et al v. Takeda Pharmaceuticals North America Inc et al	
10/21/2013	10/21/2013	3470; 314	Eighth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Kristin Kucsma, M.A., Regarding Punitive Damages</i> - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3471; 315	Ninth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert David Kessler, M.D.</i> - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/21/2013	3472; 316	SEALED MOTION <i>Defendants' Motion to File Exhibits Under Seal</i> (Attachments: # (1) Exhibit A1-A5, B1B3, B6, B9, C1, C3, C8 and D1- D4) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/21/2013	10/22/2013	3473; 317	EXHIBIT re (3464 in 6:11-md-02299-RFD-PJH) Second DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Sebastian Schneeweiss, M.D., S.M., SC.D., F.A.C.E., F.C.P., F.I.S.P.E.</i> , (3463 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3470 in 6:11-md-02299-RFD-PJH) Eighth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Kristin Kucsma, M.A., Regarding Punitive Damages</i> , (3468 in 6:11-md-02299-RFD-PJH) Sixth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Jennifer Southgate, Ph.D.</i> , (3466 in 6:11-md-02299-RFD-PJH) Fourth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Experts That Actos Can Cause Bladder Cancer Within One Year of Use</i> , (3469 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3467 in 6:11-md-02299-RFD-PJH) Fifth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dipak Panigraphy, M.D.</i> , (3465 in 6:11-md-02299-RFD-PJH) Third DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Herbert Barton Grossman, M.D.</i> , (3471 in 6:11-md-02299-RFD-PJH) Ninth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert David Kessler, M.D. Defendants' Omnibus Collection of Exhibits Referenced in Motions to Exclude Certain Testimony Filed on October 21, 2013</i> (Attachments: # (1) Exhibit A1-B11, # (2) Exhibit C1 - C4) Allen et al v. Takeda Pharmaceuticals North America Inc et	All

			al	
10/22/2013	10/22/2013	3474; 318	<p>EXHIBIT re (3464 in 6:11-md-02299-RFD-PJH) Second DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Sebastian Schneeweiss, M.D., S.M., SC.D., F.A.C.E., F.C.P., F.I.S.P.E.</i>, (3463 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3470 in 6:11-md-02299-RFD-PJH) Eighth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Kristin Kucsma, M.A., Regarding Punitive Damages</i>, (3468 in 6:11-md-02299-RFD-PJH) Sixth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Jennifer Southgate, Ph.D.</i>, (3466 in 6:11-md-02299-RFD-PJH) Fourth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Experts That Actos Can Cause Bladder Cancer Within One Year of Use</i>, (3469 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3467 in 6:11-md-02299-RFD-PJH) Fifth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dipak Panigraphy, M.D.</i>, (3465 in 6:11-md-02299-RFD-PJH) Third DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Herbert Barton Grossman, M.D.</i>, (3471 in 6:11-md-02299-RFD-PJH) Ninth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert David Kessler, M.D. Exhibits C5 - C11</i> –</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
10/22/2013	10/22/2013	3475; 319	<p>EXHIBIT re (3464 in 6:11-md-02299-RFD-PJH) Second DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Sebastian Schneeweiss, M.D., S.M., SC.D., F.A.C.E., F.C.P., F.I.S.P.E.</i>, (3463 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3470 in 6:11-md-02299-RFD-PJH) Eighth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Kristin Kucsma, M.A., Regarding Punitive Damages</i>, (3468 in 6:11-md-02299-RFD-PJH) Sixth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Jennifer Southgate, Ph.D.</i>, (3466 in 6:11-md-02299-RFD-PJH) Fourth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Experts That Actos Can Cause Bladder Cancer Within One Year of Use</i>, (3469 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3467 in 6:11-md-02299-RFD-PJH) Fifth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dipak Panigraphy, M.D.</i>, (3465 in 6:11-md-02299-RFD-PJH) Third DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Herbert Barton Grossman, M.D.</i>, (3471 in 6:11-md-02299-RFD-PJH) Ninth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert David Kessler, M.D. Exhibits C12- E3</i></p>	All

			(Attachments: # (1) Exhibit C12-C13, # (2) Exhibit D1-E3) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	
10/22/2013	10/22/2013	3476; 320	EXHIBIT re (3468 in 6:11-md-02299-RFD-PJH) Sixth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Jennifer Southgate, Ph.D.</i> , (3466 in 6:11-md-02299-RFD-PJH) Fourth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Experts That Actos Can Cause Bladder Cancer Within One Year of Use</i> , (3469 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3467 in 6:11-md-02299-RFD-PJH) Fifth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dipak Panigraphy, M.D.</i> , (3464 in 6:11-md-02299-RFD-PJH) Second DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Sebastian Schneeweiss, M.D., S.M., SC.D., F.A.C.E., F.C.P., F.I.S.P.E.</i> , (3465 in 6:11-md-02299-RFD-PJH) Third DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Herbert Barton Grossman, M.D.</i> , (3471 in 6:11-md-02299-RFD-PJH) Ninth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert David Kessler, M.D.</i> , (3463 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3470 in 6:11-md-02299-RFD-PJH) Eighth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Kristin Kucsma, M.A., Regarding Punitive Damages Exhibits F1-F8-</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/22/2013	10/22/2013	3477; 321	EXHIBIT re (3468 in 6:11-md-02299-RFD-PJH) Sixth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Jennifer Southgate, Ph.D.</i> , (3466 in 6:11-md-02299-RFD-PJH) Fourth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Experts That Actos Can Cause Bladder Cancer Within One Year of Use</i> , (3469 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3467 in 6:11-md-02299-RFD-PJH) Fifth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dipak Panigraphy, M.D.</i> , (3464 in 6:11-md-02299-RFD-PJH) Second DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Sebastian Schneeweiss, M.D., S.M., SC.D., F.A.C.E., F.C.P., F.I.S.P.E.</i> , (3465 in 6:11-md-02299-RFD-PJH) Third DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Herbert Barton Grossman, M.D.</i> , (3471 in 6:11-md-02299-RFD-PJH) Ninth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert David Kessler, M.D.</i> , (3463 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3470 in 6:11-md-02299-RFD-PJH) Eighth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Kristin Kucsma, M.A.</i> ,	All

			<p><i>Regarding Punitive Damages Exhibits F9-F19 -</i></p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	
10/22/2013	10/22/2013	3478; 322	<p>EXHIBIT re (3468 in 6:11-md-02299-RFD-PJH) Sixth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Jennifer Southgate, Ph.D.</i>, (3466 in 6:11-md-02299-RFD-PJH) Fourth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Experts That Actos Can Cause Bladder Cancer Within One Year of Use</i>, (3469 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3467 in 6:11-md-02299-RFD-PJH) Fifth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dipak Panigraphy, M.D.</i>, (3464 in 6:11-md-02299-RFD-PJH) Second DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Sebastian Schneeweiss, M.D., S.M., SC.D., F.A.C.E., F.C.P., F.I.S.P.E.</i>, (3465 in 6:11-md-02299-RFD-PJH) Third DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Herbert Barton Grossman, M.D.</i>, (3471 in 6:11-md-02299-RFD-PJH) Ninth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert David Kessler, M.D.</i>, (3463 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3470 in 6:11-md-02299-RFD-PJH) Eighth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Kristin Kucsma, M.A., Regarding Punitive Damages Exhibits F28-F29 -</i></p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
10/22/2013	10/22/2013	3479; 323	<p>EXHIBIT re (3468 in 6:11-md-02299-RFD-PJH) Sixth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Jennifer Southgate, Ph.D.</i>, (3466 in 6:11-md-02299-RFD-PJH) Fourth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Experts That Actos Can Cause Bladder Cancer Within One Year of Use</i>, (3469 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3467 in 6:11-md-02299-RFD-PJH) Fifth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dipak Panigraphy, M.D.</i>, (3464 in 6:11-md-02299-RFD-PJH) Second DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Sebastian Schneeweiss, M.D., S.M., SC.D., F.A.C.E., F.C.P., F.I.S.P.E.</i>, (3465 in 6:11-md-02299-RFD-PJH) Third DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Herbert Barton Grossman, M.D.</i>, (3471 in 6:11-md-02299-RFD-PJH) Ninth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert David Kessler, M.D.</i>, (3463 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3470 in 6:11-md-02299-RFD-PJH) Eighth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Kristin Kucsma, M.A.</i>,</p>	All

			<p><i>Regarding Punitive Damages Exhibits G1-G3 -</i></p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	
10/22/2013	10/22/2013	3480; 324	<p>EXHIBIT re (3468 in 6:11-md-02299-RFD-PJH) Sixth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Jennifer Southgate, Ph.D.</i>, (3466 in 6:11-md-02299-RFD-PJH) Fourth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Experts That Actos Can Cause Bladder Cancer Within One Year of Use</i>, (3469 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3467 in 6:11-md-02299-RFD-PJH) Fifth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Dipak Panigraphy, M.D.</i>, (3464 in 6:11-md-02299-RFD-PJH) Second DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Sebastian Schneeweiss, M.D., S.M., SC.D., F.A.C.E., F.C.P., F.I.S.P.E.</i>, (3465 in 6:11-md-02299-RFD-PJH) Third DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Herbert Barton Grossman, M.D.</i>, (3471 in 6:11-md-02299-RFD-PJH) Ninth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert David Kessler, M.D.</i>, (3463 in 6:11-md-02299-RFD-PJH) Sealed Document,, (3470 in 6:11-md-02299-RFD-PJH) Eighth DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Kristin Kucsma, M.A., Regarding Punitive Damages Exhibits F20-F27 --</i></p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
10/22/2013	10/22/2013	3481 (spread to all cases)	<p>MOTION for Leave to File Motion Under Seal with consent by PSC. Motions referred to Patrick J Hanna. (Attachments: # (1) Memorandum / Brief, # (2) Proposed order) --</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
10/22/2013	10/22/2013	3482; 326	<p>MEMORANDUM in Opposition re (3371 in 6:11-md-02299-RFD-PJH, 255 in 6:12-cv-00064-RFD-PJH) MOTION in Limine <i>to Exclude Any Mention that Lipitor is Alleged to Cause Cancer --</i></p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
10/21/2013	10/23/2013	No document attached (spread to all cases)	<p>Motions Transferred regarding (3461 in 6:11-md-02299-RFD-PJH) MOTION for Leave to File Excess Pages -</p> <p>In Re: Actos (Pioglitazone) Products Liability Litigation</p>	All
10/21/2013	10/23/2013	3489	<p>REPORT AND RECOMMENDATIONS ON REQUEST FOR DISTRIBUTION OF FUNDS. Objections to R&R due</p>	All

			by 11/7/2013. - In Re: Actos (Pioglitazone) Products Liability Litigation	
10/23/2013	10/23/2013	3490; 26; 26; 26; 26; 26; 26	ANSWER to Multi-plaintiff Complaint with Jury Demand.: Cline v. Takeda Pharmaceuticals America Inc et al Darcy v. Takeda Pharmaceuticals America Inc et al Davis et al v. Takeda Pharmaceuticals America Inc et al Lee v. Takeda Pharmaceuticals America Inc et al Lynch v. Takeda Pharmaceuticals America Inc et al Propp v. Takeda Pharmaceuticals America Inc et al	All
10/23/2013	10/23/2013	3491; 50; 50; 50	ANSWER to Multi-plaintiff Complaint with Jury Demand.: Combs v. Takeda Pharmaceuticals U S A Inc et al Ferris v. Takeda Pharmaceuticals U S A Inc et al Foster v. Takeda Pharmaceuticals U S A Inc et al	All
10/23/2013	10/23/2013	3492; 200	ANSWER to Plaintiff's Amended Complaint with Jury Demand. Gregoria et al v. Takeda Pharmaceuticals North America Inc et al	All
10/23/2013	10/23/2013	3493; 333	MEMORANDUM in Opposition re (258 in 6:12-cv-00064-RFD-PJH, 3374 in 6:11-md-02299-RFD-PJH) MOTION in Limine to Preclude Testimony/Argument that Lack of Statements by the FDA and Other Entities Such as the ADA, ACA, SUO, AUA, ASCO, CDC, NIH and URH is Evidence Regarding General Causation with Respect to Actos Causing Bladder Cancer - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/23/2013	10/23/2013	3494; 334	MOTION for Leave to File Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Scott Delacroix Under Seal [D.E. 3463] with consent - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/23/2013	10/23/2013	3496 (Spread to all cases)	NOTICE of Defendants' Service List – In Re: Actos (Pioglitazone) Products Liability Litigation	All

10/24/2013	10/24/2013	3497; 19	PROOF OF SERVICE of Complaint; Estrade et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/24/2013	10/24/2013	3498; 12	PROOF OF SERVICE of Complaint; Baker v. Takeda Pharmaceuticals America Inc et al	All
10/22/2013	10/24/2013	No Document Attached	Motions Transferred regarding [3494] MOTION for Leave to File Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Scott Delacroix Under Seal [D.E. 3463] with consent, [3481] MOTION for Leave to File Motion Under Seal with consent, [3487] MOTION for Leave to File Plaintiffs Response to Defendants Motion in Limine to Exclude Any Evidence and Argument Regarding the Attendance or Non-Attendance of Certain Witnesses at Trial with Exhibits A-D with consent, and [3485] MOTION for Leave to File Plaintiffs Response to Defendants Motion In Limine to Exclude Any Argument Regarding Witnesses Testifying By Deposition with Exhibits A-F with consent. Motions referred to Magistrate Judge Patrick J Hanna. In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/22/2013	10/24/2013	No Document Attached	Motions Transferred regarding [3495] MOTION for Leave to File Defendants' Motion to Exclude Testimony of Plaintiffs' Experts David Altman, M.D., Dan Bagwell, R.N., and Kristin Kucsma, M.A., Regarding "Outcome Scenario II" Under Seal [D.E. 3469] with consent. In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/21/2013	10/24/2013	No Document Attached	Motion Transferred regarding [3456] MOTION for Leave to File Sealed Motion In Limine with consent. In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/25/2013	10/25/2013	3499; 337	PROPOSED ORDER/JUDGMENT <i>Regarding Defendants Motion for Leave to File Exhibits A1-A5, B1-B3, B6, B9, C1, C3, C8 and D1- D4 to Defendants' motions to exclude certain testimony offered by Plaintiffs putative expert witnesses Under Seal [D.E. 3472]</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/25/2013	10/25/2013	3500; 338	ORDER granting (3456) Motion for Leave to File to File Motion in Liminie under seal Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/25/2013	10/25/2013	3501; 339	ORDER granting (3485) Motion for Leave to File Allen et al v. Takeda Pharmaceuticals North America Inc et	All

			al	
10/25/2013	10/25/2013	No Document Attached	Motion Transferred regarding (303 in 6:12-cv-00064-RFD-PJH, 3457 in 6:11-md-02299-RFD-PJH) SEALED MOTION Plaintiffs Motion in Limine Motion referred to Judge Rebecca F Doherty. Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/28/2013	10/28/2013	3502; 87	PROOF OF SERVICE of Affidavit of Service of Summons and Complaint Taylor et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/28/2013	10/28/2013	3503 (spread to all cases)	SUPPLEMENTAL MEMORANDUM in Support re [3481] MOTION for Leave to File Motion Under Seal with consent filed by PSC. In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/28/2013	10/28/2013	3504; 22; 22	ANSWER to Plaintiffs' Complaint with Jury Demand. Beasley et al v. Takeda Pharmaceuticals America Inc et al; Clemmons v. Takeda Pharmaceuticals America Inc et al	All
10/28/2013	10/28/2013	3505; 14	NOTICE by Charlotte Calvert of Certificate of Good Standing of <i>Attorney Sarah J. Showard</i> Calvert v. Takeda Pharmaceuticals U S A Inc et al	All
10/28/2013	10/28/2013	3506; 21	ANSWER to Plaintiffs' Complaint with Jury Demand. Conti et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/28/2013	10/28/2013	3507; 64	ANSWER to Plaintiff's Complaint with Jury Demand. - Griffin v. Takeda Pharmaceuticals U S A Inc et al	All
10/28/2013	10/28/2013	3508; 19	ANSWER to Plaintiffs' Complaint with Jury Demand. - Laconto et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/28/2013	10/28/2013	No Document Number	Actos "Spread to all" function In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/28/2013	10/29/2013	3509 (spread to all cases)	MOTION for Leave to File Excess Pages and <i>Opposition to the PSC's Spoliation and Rule 37 Motion for Sanctions and all Accompanying Exhibits Under Seal</i> , SEALED MOTION	All

			by Takeda - In Re: Actos (Pioglitazone) Products Liability Litigation	
10/25/2013	10/29/2013	3510; 341	ORDER granting (3472) Sealed Motion and (316) Sealed Motion in case 6:12-cv-00064-RFD-PJH for Leave of Court to File Plaintiffs Response to Defendants Motion in Limine to Exclude Any Evidence and Argument Regarding the Attendance or Non-Attendance of Certain Witnesses at Trial with Exhibits A-D case Under Seal. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/25/2013	10/29/2013	3511; 342	ORDER granting (3494) Motion for Leave to File in case 6:11-md-02299-RFD-PJH; and (334) Motion for Leave to File in case 6:12-cv-00064-RFD-PJH to Exclude Testimony of Plaintiffs Expert Dr. Scott Delacroix Under Seal. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/25/2013	10/29/2013	3512; 343	ORDER granting (3495) Motion for Leave in case 6:11-md-02299-RFD-PJH and (335) Motion for Leave in case 6:12-cv-00064-RFD-PJH to File Defendants Motion to Exclude Testimony of Plaintiffs Experts David Altman, M.D., Dan Bagwell, R.N., and Kristin Kucsma, M.A., Regarding Outcome Scenario II Under Seal. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/25/2013	10/29/2013	3513; 203	ORDER granting (3360) Motion to Substitute Party and Motion to Amend Complaint - Gregoria et al v. Takeda Pharmaceuticals North America Inc et al	All
10/29/2013	10/29/2013	3514; 112	MOTION to Substitute Party with consent by David E Smith, Regina M Smith.- Smith et al v. Takeda Pharmaceuticals U S A Inc et al	All
10/29/2013	10/29/2013	3515; 344	REPLY to Response to Motion re (296 in 6:12-cv-00064-RFD-PJH, 3438 in 6:11-md-02299-RFD-PJH) MOTION in Limine <i>Defendants' Motion in Limine to Exclude Evidence or Argument Regarding the Attendance or Non-Attendance of Certain Witnesses at Trial</i> filed by Lilly, Takeda - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/29/2013	10/29/2013	3516; 345	REPLY to Response to Motion re (3368 in 6:11-md-02299-RFD-PJH, 252 in 6:12-cv-00064-RFD-PJH) MOTION in Limine <i>To Exclude Argument Regarding Witnesses</i>	All

			<p><i>Testifying by Deposition</i> filed by Lilly, Takeda-</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	
10/29/2013	10/29/2013	3517; (spread to all cases)	<p>ORDER granting (3481) for Leave to File Motion Under Seal with consent by PSC. Signed by Magistrate Judge Patrick J Hanna on 10/29/13. IT IS HEREBY ORDERED that the PSC be and are hereby granted leave to file its Spoliation and Rule 37 Motion for Sanctions, Memorandum in Support and all accompanying exhibits under seal. -</p> <p>In Re: Actos (Pioglitazone) Products Liability Litigation</p>	All
10/30/2013	10/30/2013	3518; 5	<p>AMENDED COMPLAINT -</p> <p>Sicard v Takeda Pharmaceuticals USA Inc et, al</p>	All
10/30/2013	10/30/2013	3519; 41; 41; 41; 41; 41	<p>PROOF OF SERVICE of Summons, , Bundled Complaint, Severance Order</p> <p>Barbano et al v. Takeda Pharmaceuticals America Inc et al;</p> <p>Brenton et al v. Takeda Pharmaceuticals America Inc et al;</p> <p>Butsky et al v. Takeda Pharmaceuticals America Inc et al;</p> <p>Hudson et al v. Takeda Pharmaceuticals America Inc et al;</p> <p>McCalister et al v. Takeda Pharmaceuticals America Inc et al</p>	All
10/30/2013	10/30/2013	3520; 347	<p>REPLY to Response to Motion re (258) (3374) in MOTION in Limine to Preclude Testimony/Argument that Lack of Statements by the FDA and Other Entities Such as the ADA, ACA, SUO, AUA, ASCO, CDC, NIH and URH is Evidence Regarding General Causation with Respect to Actos Causing Bladder Cancer filed by PSC. (Attachments: # (1) Exhibit A-E) -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
10/30/2013	10/30/2013	3521; 348	<p>Unopposed MOTION to Withdraw (3457) SEALED MOTION <i>Plaintiffs Motion in Limine to Exclude any Evidence or Discussion of the General Cardiovascular Risks of Type 2 Diabetes and Related Statistics while and also Claiming, Implying or Suggesting that Actos Reduces Such Risk in the Same P</i> by PSC -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
10/30/2013	10/30/2013	3522; 81	<p>ANSWER to Plaintiff's Complaint -</p>	All

			Ross v. Takeda Pharmaceuticals America Inc et al	
10/30/2013	10/30/2013	3523; 68	ANSWER to Plaintiffs' Complaint - Schneider et al v. Takeda Pharmaceuticals America Inc et al	All
10/30/2013	10/30/2013	3524; 349	ORDER granting (3487) Motion for Leave to File Plaintiffs Response to Defendants Motion in Limine to Exclude Any Evidence and Argument Regarding the Attendance or Non-Attendance of Certain Witnesses at Trial with Exhibits A-D Under Seal;- Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/30/2013	10/30/2013	3525; 350	ORDER withdrawing (3336) Motion in Limine to Exclude Any Reference to whether Terrence Allen's Medical Expenses are Covered by Some Form of Insurance - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/30/2013	10/30/2013	3526 ; (spread to all cases)	ORDER granting : 6:11-md-02299-RFD-PJH [3509]MOTION for Leave to File Excess Pages and Opposition to the PSC's Spoliation and Rule 37 Motion for Sanctions and all Accompanying Exhibits Under Seal. Signed by Magistrate Judge Patrick J Hanna on 10/30/13. - In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/30/2013	10/31/2013	No Document Attached	Motion Transferred regarding (348 in 6:12-cv-00064-RFD-PJH, and 3521 in 6:11-md-02299-RFD-PJH) Unopposed MOTION to Withdraw (3457 in 6:11-md-02299-RFD-PJH) SEALED MOTION <i>Plaintiffs Motion in Limine to Exclude any Evidence or Discussion of the General Cardiovascular Risks of Type 2 Diabetes and Related Statistics while and also Claiming,-</i> Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
10/31/2013	10/31/2013	3527; 22	NOTICE of Voluntary Dismissal Without Prejudice re: Defendant Takeda California, Inc., f/k/a Takeda San Diego, Inc. - Larson v. Takeda Pharmaceuticals U S A Inc et al	All
10/31/2013	10/31/2013	3528: 3	NOTICE by Brian Gasper of CERTIFICATE OF GOOD STANDING - Gasper et al v. Takeda California Inc et al	All
10/31/2013	10/31/2013	3529; 115	ORDER granting (3514) Motion to Substitute Party in case . Sandra Sheridan, as Executor of the Estate of David E. Smith, shall be substituted as Plaintiff for David E. Smith,	All

			deceased. Further, Plaintiffs Motion to Amend the Complaint is granted. – Smith et al v. Takeda Pharmaceuticals U S A Inc et al	
10/30/2013	10/31/2013	3530; (spread to all cases)	SEALED DOCUMENT: Opposition to Plaintiff's Spoliation and Rule 37 Motion for Sanctions by Takeda Pharmaceuticals U S A Inc, et al re (3484 in 6:11-md-02299-RFD-PJH) SEALED MOTION. - In Re: Actos (Pioglitazone) Products Liability Litigation	All
10/31/2013	10/31/2013	3531; 353	NOTICE OF FILING OF OFFICIAL TRANSCRIPT of Proceedings filed for TELEPHONE CONFERENCE ON MOTIONS IN LIMINE held on 10/28/2013 before Judge Rebecca F. Doherty- Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/1/2013	11/1/2013	3532; 354	SEALED MOTION by Susan Allen, Terrence Allen. Motions referred to Patrick J Hanna. (Attachments: # (1) Memorandum / Brief, # (2) Proposed pleading Memorandum in Opposition, # (3) Statement of material facts, # (4) Exhibit 1-20, # (5) Exhibit 21-31, # (6) Exhibit 32-39, # (7) Exhibit 40 (Part 1 of 3), # (8) Exhibit 40 (Part 2 of 3), # (9) Exhibit 40 (Part 3 of 3) - 43, # (10) Exhibit 44 (Part 1 of 2), # (11) Exhibit 44 (Part 2 of 2), # (12) Exhibit 45-48, # (13) Exhibit 49-74, # (14) Exhibit 75-80 (Part 1), # (15) Exhibit 80 (Part 2) - 85, # (16) Exhibit 86-91, # (17) Exhibit 92-106, # (18) Exhibit 107-131, # (19) Exhibit 132-160, # (20) Exhibit 161-172, # (21) Proposed order) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/2/2013	11/2/2013	3533; 355	SEALED MOTION by Susan Allen, Terrence Allen. Motions referred to Patrick J Hanna. (Attachments: # (1) Memorandum / Brief, # (2) Proposed pleading Memorandum in Opposition, # (3) Statement of material facts Response to Defendants' Statement of Facts, # (4) Statement of material facts Plaintiffs' Statement of Contested Facts, # (5) Exhibit 1 - 3 (part 1 of 2), # (6) Exhibit 3 (part 2 of 2 - 12), # (7) Exhibit 13-30, # (8) Exhibit 31-37, # (9) Exhibit 38-60, # (10) Exhibit 61-70, # (11) Exhibit 71, # (12) Exhibit 72-80, # (13) Exhibit 81-100, # (14) Exhibit 101-109, # (15) Exhibit 110-154, # (16) Proposed order) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/4/2013	11/4/2013	3534; 117	AMENDED COMPLAINT against All Defendants with Jury Demand filed by David E Smith Estate - Smith et al v. Takeda Pharmaceuticals U S A Inc et al	All

11/4/2013	11/4/2013	3535; 9	PROOF OF SERVICE of Civil Case Cover Sheet and Complaint upon Takeda Pharmaceutical Company Ltd. - Chambers et al v Takeda Pharmaceuticals North America Inc et al	All
11/4/2013	11/4/2013	3536; 10	PROOF OF SERVICE of Civil Case Cover Sheet and Complaint upon Takeda Pharmaceutical North America - Chambers et al v Takeda Pharmaceuticals North America Inc et al	All
11/4/2013	11/4/2013	3537; 11	PROOF OF SERVICE of Civil Case Cover Sheet and Complaint upon Takeda Pharmaceuticals America, Inc. - Chambers et al v Takeda Pharmaceuticals North America Inc et al	All
11/5/2013	11/5/2013	3538; 356	ORDER granting (3533) Sealed Motion (355) Sealed Motion Signed by Magistrate Judge Patrick J Hanna on 11/5/13. IT IS HEREBY ORDERED that Plaintiffs Motion for Leave to Exceed the Page Limit, From 25 Pages to 45 Pages, and to file under seal their opposition to Defendants Motion for Partial Summary Judgment (Doc. 3411), Statements of Contested Facts and all accompanying exhibits, is GRANTED. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/5/2013	11/5/2013	3539; 357	MEMORANDUM RULING regarding Motions in Liminie. Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/5/2013	11/5/2013	3540	ORDER: Considering the foregoing memorandum ruling, In Re: Actos (Pioglitazone) Products Liability Litigation	All
11/5/2013	11/5/2013	3541; 358	SEALED MOTION <i>To file Under Seal Exhibit 6 to Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Adriane Fugh-Burman</i> (Attachments: # (1) Proposed order, # (2) Exhibit 6) – Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/5/2013	11/5/2013	3542; 359	DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Adriane Fugh-Berman</i> - (Attachments: # <u>1</u> Memorandum / Brief, # <u>2</u> Proposed order, # <u>3</u> Exhibit 1-10) – Allen et al v. Takeda Pharmaceuticals North America Inc et al	All

11/5/2013	11/5/2013	3543; (spread to all cases)	SEALED MOTION by PSC. Motions referred to Patrick J Hanna. (Attachments: # (1) Memorandum / Brief, # (2) Proposed pleading Reply Brief, # (3) Exhibit 33-40, # (4) Proposed order) - In Re: Actos (Pioglitazone) Products Liability Litigation	All
11/5/2013	11/6/2013	3544	ORDER granting [3532] Sealed Motion to Exceed the Page Limit From 25 Pages to 35 Pages and to File the Opposition to Defendant's Motion for Summary Judgment Under Seal.- In Re: Actos (Pioglitazone) Products Liability Litigation	All
11/5/2013	11/6/2013	3545; 361	SEALED DOCUMENT: Plaintiffs' Memorandum in Opposition to Motion for Summary Judgment by Susan Allen and Terrence Allen re (3415 in 6:11-md-02299-RFD-PJH) SEALED MOTION <i>Defendants' Motion for Summary Judgment</i> . (Attachments: # (1) Statement of material facts, # (2) Exhibit 1-20, # (3) Exhibit 21-31, # (4) Exhibit 32-39, # (5) Exhibit 40 (Part 1 of 3), # (6) Exhibit 40 (Part 2 of 3), # (7) Exhibit 40 (Part 3 of 3) - 43, # (8) Exhibit 44 (Part 1 of 2), # (9) Exhibit 44 (Part 2 of 2), # (10) Exhibit 45-48, # (11) Exhibit 49-74, # (12) Exhibit 75-80 (Part 1), # (13) Exhibit 80 (Part 2) - 85, # (14) Exhibit 86-91, # (15) Exhibit 92-106, # (16) Exhibit 107-131, # (17) Exhibit 132-160, # (18) Exhibit 161-172) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/6/2013	11/6/2013	3546; 362	MEMORANDUM in Opposition re (279 in 6:12-cv-00064-RFD-PJH, 3414 in 6:11-md-02299-RFD-PJH) MOTION in Limine <i>to Exclude Any Reference to Payments Made to Plaintiff Allens Treating Doctor for his Time During Deposition, Preparation, and for his Review of Medical Literature</i> filed by Defendants (Attachments: # (1) Exhibit A and B) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/6/2013	11/6/2013	3547; 363	MEMORANDUM in Opposition re (293 in 6:12-cv-00064-RFD-PJH, 3428 in 6:11-md-02299-RFD-PJH) MOTION in Limine <i>to Exclude Any Evidence That Pioglitazone is Beneficial to or Decreases the Risk of Certain Types of Cancer</i> filed by Defendants (Attachments: # (1) Exhibit A - E) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/6/2013	11/6/2013	3548; 364	MEMORANDUM in Opposition re (295 in 6:12-cv-00064-RFD-PJH, 3430 in 6:11-md-02299-RFD-PJH) MOTION in Limine <i>to Exclude Evidence or Testimony to the July/August 2013 AACE/ACE Diabetes and Cancer</i>	All

			<p><i>Consensus Statement</i> filed by Defendants (Attachments: # (1) Exhibit A - E)-</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	
11/5/2013	11/6/2013	3549; 365	<p>SEALED DOCUMENT: Plaintiffs' Memorandum in Opposition to Defendant's Motion for Partial Summary Judgment on all Claims for Relief and Allegations Based Upon Failure to Warn Federal Preemption by Susan Allen and Terrence Allen re (3411 in 6:11-md-02299-RFD-PJH) <i>MOTION for Partial Summary Judgment Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption)</i>. (Attachments: # (1) Statement of material facts Response to Defendants' Statement of Facts, # (2) Statement of material facts Plaintiffs' Statement of Contested Facts, # (3) Exhibit 1 - 3 (part 1 of 2), # (4) Exhibit 3 (part 2 of 2 - 12), # (5) Exhibit 13-30, # (6) Exhibit 31-37, # (7) Exhibit 38-60, # (8) Exhibit 61-70, # (9) Exhibit 71, # (10) Exhibit 72-80, # (11) Exhibit 81-100, # (12) Exhibit 101-109, # (13) Exhibit 110-154) -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/6/2013	11/6/2013	3550; 366	<p>ORDER granting (3541) Sealed Motion in case 6:11-md-02299-RFD-PJH and in case 6:12-cv-00064-RFD-PJH. Having Considered the foregoing Motion for Leave of Court to File Defendants Motion for Leave to File Exhibit 6 to Defendants Motion to Exclude Testimony of Plaintiffs Expert Adriane Fugh-Burman Under Seal; IT IS HEREBY ORDERED that the motion is granted and Defendants are given leave to file Exhibit 6 Under Seal. -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/5/2013	11/6/2013	3551	<p>ORDER adopting [3445] Report and Recommendations on Distribution of Funds. –</p> <p>In Re: Actos (Pioglitazone) Products Liability Litigation</p>	All
11/6/2013	11/6/2013	3552; 367	<p>MEMORANDUM in Opposition re (3420 in 6:11-md-02299-RFD-PJH, 285 in 6:12-cv-00064-RFD-PJH) <i>MOTION in Limine to Exclude Any Reference to Product Labeling and Other Evidence of Pharmaceutical Drugs Taken by Plaintiff Other than Actos</i> filed Defendants (Attachments: # (1) Exhibit A-C) -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/6/2013	11/6/2013	3553; 368	<p>MEMORANDUM in Opposition re (3412 in 6:11-md-02299-RFD-PJH, 277 in 6:12-cv-00064-RFD-PJH)</p>	All

			<p>MOTION in Limine to Exclude as Irrelevant and Prejudicial any Evidence or Reference Concerning Rare Fatal Side-Effects of Commonly Used Over-The-Counter (OTC) Drugs filed by Defendants (Attachments: # (1) Exhibit A-C) -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	
11/6/2013	11/6/2013	3554; 5	<p>AMENDED COMPLAINT against Defendants with Jury Demand</p> <p>- Rizk et al v. Takeda Pharmaceuticals America Inc et al</p>	All
11/5/2013	11/6/2013	3555; (spread to all cases)	<p>ORDER adopting (3440) Report and Recommendations on Distribution of Funds in case 6:11-md-02299-RFD-PJH, et al. Signed by Judge Rebecca F Doherty on 11/5/13. -</p> <p>In Re: Actos (Pioglitazone) Products Liability Litigation</p>	All
11/7/2013	11/7/2013	3556; 370	<p>MOTION for Leave to File Under Seal PLAINTIFFS MEMORANDUM OF LAW IN OPPOSITION TO DEFENDANTS MOTION IN LIMINE TO EXCLUDE EVIDENCE AND ARGUMENT REGARDING ADVERSE EVENT REPORTS with consent by PSC. -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/7/2013	11/7/2013	3557; 371	<p>SEALED DOCUMENT: PLAINTIFFS MEMORANDUM OF LAW IN OPPOSITION TO DEFENDANTS MOTION IN LIMINE TO EXCLUDE EVIDENCE AND ARGUMENT REGARDING ADVERSE EVENT REPORTS by PSC re (3403 in 6:11-md-02299-RFD-PJH) MOTION in Limine <i>Defendants' Motion in Limine to Exclude Certain Evidence and Argument regarding Adverse Event Reports</i>. (Attachments: # (1) Exhibit A-D) -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/7/2013	11/7/2013	3558; 372	<p>MOTION for Leave to File Under Seal PLAINTIFFS MEMORANDUM OF LAW IN OPPOSITION TO DEFENDANTS MOTION IN LIMINE TO EXCLUDE THE TESTIMONY OF DR. HELEN GE with consent by PSC. (Attachments: # (1) Proposed order) -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/7/2013	11/7/2013	3559; 373	<p>SEALED DOCUMENT: PLAINTIFFS MEMORANDUM OF LAW IN OPPOSITION TO DEFENDANTS MOTION IN LIMINE TO EXCLUDE THE TESTIMONY OF HELEN GE by PSC re (3408 in 6:11-md-02299-RFD-PJH) MOTION in Limine <i>Defendants' Motion in Limine to</i></p>	All

			<p><i>Exclude the Testimony of Helen Ge.</i> (Attachments: # (1) Exhibit A-D) -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	
11/7/2013	11/7/2013	3560; 374	<p>MOTION for Leave to File Under Seal PLAINTIFFS MEMORANDUM OF LAW IN OPPOSITION TO DEFENDANTS MOTION IN LIMINE TO EXCLUDE EVIDENCE AND ARGUMENT REGARDING TAKEDA OR ELI LILLY DRUGS WITHDRAWN FROM THE MARKET with consent by PSC. (Attachments: # (1) Proposed order) -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/7/2013	11/7/2013	3561; 365	<p>SEALED DOCUMENT: Plaintiffs Memorandum of Law in Opposition to Defense Motion in Limine to Exclude Evidence and Argument regarding Takeda or Eli Lilly Drugs Withdrawn from the Market by PSC re (3404 in 6:11-md-02299-RFD-PJH) MOTION in Limine <i>Defendants' Motion in Limine to Exclude Evidence and Argument regarding Takeda or Eli Lilly Drugs Withdrawn from the Market.</i> (Attachments: # (1) Exhibit A) -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/6/2013	11/7/2013	3562; 376	<p>SEALED DOCUMENT: Sealed Exhibit 6 by Defendants re (359 in 6:12-cv-00064-RFD-PJH and 3542 in 6:11-md-02299-RFD-PJH) DAUBERT MOTION <i>Defendants' Motion to Exclude Testimony of Plaintiffs' Expert Adriane Fugh-Berman.</i> -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/7/2013	11/7/2013	3563; 170	<p>MEMORANDUM AND CERTIFICATION ORDER. Signed by Judge Rebecca F Doherty on 11/7/13.</p> <p>Bowerman v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/7/2013	11/7/2013	3564; 171	<p>ORDER deferring ruling on (2793) Motion to Dismiss for Failure to State a Claim in case 6:11-md-02299-RFD-PJH and (98) Motion to Dismiss for Failure to State a Claim in case 6:12-cv-01590-RFD-PJH pending resolutio of the certified questions of law by the Arkansas Supreme Court. Signed by Judge Rebecca F Doherty on 11/7/13 -</p> <p>Bowerman v. Takeda Pharmaceuticals North America Inc et al</p>	All

11/7/2013	11/7/2013	3565; 73; 73; 73; 62; 73; 73; 73; 73; 73; 73; 73	ANSWER to Multi-plaintiff Complaint with Jury Demand. Harris et al v. Takeda Pharmaceuticals America Inc et al Wicks et al v. Takeda Pharmaceuticals America Inc et al Parker v. Takeda Pharmaceuticals America Inc et al Nardelli v. Takeda Pharmaceuticals America Inc et al Frazier et al v. Takeda Pharmaceuticals America Inc et al Heard et al v. Takeda Pharmaceuticals America Inc et al Piazza et al v. Takeda Pharmaceuticals America Inc et al Cordero et al v. Takeda Pharmaceuticals America Inc et al Hernandez et al v. Takeda Pharmaceuticals America Inc et al Fondren et al v. Takeda Pharmaceuticals America Inc et al	All
11/7/2013	11/7/2013	3566; 74	ANSWER to Plaintiffs' Complaint with Jury Demand.- Cruz et al v. Takeda Pharmaceuticals America Inc et al	All
11/7/2013	11/7/2013	3567; 74	ANSWER to Plaintiffs' Complaint with Jury Demand.- Howe et al v. Takeda Pharmaceuticals America Inc et al	All
11/6/2013	11/7/2013	3568; (spread to all cases)	ORDER granting (3543) Sealed Motion in case 6:11-md-02299-RFD-PJH et al. Good cause appearing, IT IS HEREBY ORDERED that the PSC Motion for Leave to Exceed the Page Limit, From 20 to 23 Pages, and to file under seal a Reply Brief in Support of Spoliation and Rule 37 Motion for Sanctions and accompanying exhibits under seal is GRANTED. Signed by Magistrate Judge Patrick J Hanna on 11/6/13. In Re: Actos (Pioglitazone) Products Liability Litigation	All
11/6/2013	11/7/2013	3569: (spread to all cases)	SEALED DOCUMENT: Reply Brief in Support of Spoliation and Rule 37 Motion for Sanctions by PSC. (Attachments: # (1) Exhibit) - In Re: Actos (Pioglitazone) Products Liability Litigation	All
11/7/2013	11/8/2013	No document attached	Motions Transferred regarding [3556] MOTION Plaintiffs Memorandum of Law in Opposition to Defendants Motion in Limine to Exclude Evidence and Argument Regarding Adverse Event Reports with consent , [3560] MOTION for Leave to File under Seal Plaintiffs Memorandum of Law in Opposition to Defendants Motion in Limine to Exclude the	All

			<p>Testimony of Dr. Helen Ge with consent, [3558] MOTION for Leave to File under Seal Plaintiffs Memorandum of Law in Opposition to Defendants Motion in Limine to Exclude Evidence and Argument Regarding Takeda or Eli Lilly Drugs Withdrawn from the Market with Consent . Motions referred to Magistrate Judge Patrick J Hanna. -</p> <p>In Re: Actos (Pioglitazone) Products Liability Litigation</p>	
11/8/2013	11/8/2013	3570; 76	<p>ANSWER to Plaintiff's Complaint with Jury Demand.</p> <p>Purtee v. Takeda Pharmaceuticals America Inc et al</p>	All
11/8/2013	11/8/2013	3571; 76	<p>ANSWER to Plaintiffs' Amended Complaint with Jury Demand.-</p> <p>Westell et al v. Takeda Pharmaceuticals America Inc et al</p>	All
11/8/2013	11/8/2013	3572; 379	<p>ORDER granting (3556) Motion for Leave to File Plaintiffs Memorandum of Law in Opposition to Defense Motion in Limine to Exclude Certain Evidence and Argument regarding Adverse Event Reports, with Exhibits A-D Under Seal -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/8/2013	11/8/2013	3573; 380	<p>ORDER granting (3558) Motion for Leave to File Plaintiffs Memorandum of Law in Opposition to Defense Motion in Limine to Exclude the Testimony of Helen Ge with Exhibits A-D Under Seal; -</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/8/2013	11/8/2013	3574; 381	<p>ORDER granting (3560) Motion for Leave to File in case 6:11-md-02299-RFD-PJH; and (374) in case 6:12-cv-00064-RFD-PJH Plaintiffs Memorandum of Law in Opposition to Defense Motion in Limine to Exclude Evidence and Argument regarding Takeda or Eli Lilly Drugs Withdrawn from the Market with Exhibit A Under Seal.</p> <p>Allen et al v. Takeda Pharmaceuticals North America Inc et al</p>	All
11/11/2013	11/11/2013	3575; 382	<p>REPLY to Response to Motion re (3411 in 6:11-md-02299-RFD-PJH, 276 in 6:12-cv-00064-RFD-PJH) MOTION for Partial Summary Judgment <i>Defendants' Motion for Partial Summary Judgment on All Claims for Relief and Allegations Based Upon Failure to Warn (Federal Preemption)</i> filed by Defendants</p> <p>- Allen et al v. Takeda Pharmaceuticals North America Inc</p>	All

			et al	
11/11/2013	11/11/2013	3576; 383	MOTION to Strike (3549 in 6:11-md-02299-RFD-PJH) Sealed Document,,, <i>Statement of Material Facts by Plaintiffs' In opposition to Defendants' Motion for Summary Judgment on Preemption</i> by Defendants - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/13/2013	11/13/2013	3577; 384	MEMORANDUM RULING re Motions in Limine: (3403 - 3409 in 6:11-md-02299-RFD-PJH), (3412 in 6:11-md-02299-RFD-PJH), (3414 in 6:11-md-02299-RFD-PJH), (3420 in 6:11-md-02299-RFD-PJH), (3428-3429 in 6:11-md-02299-RFD-PJH) and (3430 in 6:11-md-02299-RFD-PJH). - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/13/2013	11/13/2013	3578; 385	ORDER deferring ruling on (3403) Motion in Limine; deferring ruling on (3404) Motion in Limine; deferring ruling on (3405) Motion in Limine; deferring ruling on (3406) Motion in Limine; granting (3407) Motion in Limine; deferring ruling on (3408) Motion in Limine; granting (3409) Motion in Limine; deferring ruling on (3412) Motion in Limine; deferring ruling on (3414) Motion in Limine; deferring ruling on (3420) Motion in Limine; deferring ruling on (3428) Motion in Limine; denying (3429) Motion in Limine; deferring ruling on (3430) Motion in Limine in case 6:11-md-02299-RFD-PJH; deferring ruling on (268) Motion in Limine; deferring ruling on (269) Motion in Limine; deferring ruling on (270) Motion in Limine; deferring ruling on (271) Motion in Limine; granting (272) Motion in Limine; deferring ruling on (273) Motion in Limine; granting (274) Motion in Limine; deferring ruling on (277) Motion in Limine; deferring ruling on (279) Motion in Limine; deferring ruling on (285) Motion in Limine; deferring ruling on (293) Motion in Limine; denying (294) Motion in Limine; deferring ruling on (295) Motion in Limine in case 6:12-cv-00064-RFD-PJH. Signed by Judge Rebecca F Doherty on 11/13/13. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/13/2013	11/13/2013	3579; 386	REPLY to Response to Motion re (3403 in 6:11-md-02299-RFD-PJH, 268 in 6:12-cv-00064-RFD-PJH) MOTION in Limine <i>Defendants' Motion in Limine to Exclude Certain Evidence and Argument regarding Adverse Event Reports</i> filed by Defendants (Attachments: # (1) Exhibit A) – Allen et al v. Takeda Pharmaceuticals North America Inc et	All

11/13/2013	11/13/2013	3580; 387	MOTION for Leave to File Reply in Support of Defendants' Motion in Limine to Exclude Evidence and Argument regarding Takeda or Eli Lilly's Drugs withdrawn from the Market with consent by Defendants (Attachments: # (1) Proposed order, # (2) Memorandum / Brief) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/13/2013	11/13/2013	3581; 388	REPLY to Response to Motion re (279 in 6:12-cv-00064-RFD-PJH, 3414 in 6:11-md-02299-RFD-PJH) MOTION in Limine to Exclude Any Reference to Payments Made to Plaintiff Allens Treating Doctor for his Time During Deposition, Preparation, and for his Review of Medical Literature filed by PSC. (Attachments: # (1) Exhibit A) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/13/2013	11/13/2013	3582; 389	REPLY to Response to Motion re (3412 in 6:11-md-02299-RFD-PJH, 277 in 6:12-cv-00064-RFD-PJH) MOTION in Limine to Exclude as Irrelevant and Prejudicial any Evidence or Reference Concerning Rare Fatal Side-Effects of Commonly Used Over-The-Counter (OTC) Drugs filed by PSC. (Attachments: # (1) Exhibit A-C) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/13/2013	11/13/2013	3583; 390	SEALED MOTION Reply in Support of Defendants' Motion in Limine to Exclude the Testimony of Helen Ge by Eli Lilly & Co, Takeda California Inc, Takeda Development Center Americas Inc, Takeda Pharmaceutical Co Ltd, Takeda Pharmaceuticals International Inc, Takeda Pharmaceuticals L L C, Takeda Pharmaceuticals U S A Inc. Motions referred to Patrick J Hanna. (Attachments: # (1) Proposed order, # (2) Memorandum / Brief, # (3) Exhibit A) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/13/2013	11/13/2013	3584; 391	REPLY to Response to Motion re (3430 in 6:11-md-02299-RFD-PJH, 295 in 6:12-cv-00064-RFD-PJH) MOTION in Limine to Exclude Evidence or Testimony to the July/August 2013 AACE/ACE Diabetes and Cancer Consensus Statement filed by PSC. (Attachments: # (1) Exhibit A-C) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/13/2013	11/13//2013	3585	REPORT AND RECOMMENDATIONS ON REQUEST FOR DISTRIBUTION OF FUNDS. Objections to R&R due	All

			by 12/2/2013. Signed by Magistrate Judge Patrick J Hanna on 11/13/13. (Attachments: # (1) Statement of Services Rendered October 2013)(crt,Brown, A) – In Re: Actos (Pioglitazone) Products Liability Litigation	
11/13/2013	11/13/2013	3586; 392	REPLY to Response to Motion re (285 in 6:12-cv-00064-RFD-PJH, 3420 in 6:11-md-02299-RFD-PJH) MOTION in Limine to Exclude Any Reference to Product Labeling and Other Evidence of Pharmaceutical Drugs Taken by Plaintiff Other than Actos filed by PSC. (Attachments: # (1) Exhibit A-B) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/13/2013	11/13/2013	3587; 393	REPLY to Response to Motion re (3428 in 6:11-md-02299-RFD-PJH, 293 in 6:12-cv-00064-RFD-PJH) MOTION in Limine to Exclude Any Evidence That Pioglitazone is Beneficial to or Decreases the Risk of Certain Types of Cancer filed by PSC. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/14/2013	11/14/2013	3588; 27	ANSWER to Plaintiff's Complaint with Jury Demand. by Takeda Pharmaceuticals U S A Inc, Eli Lilly & Co, Takeda Pharmaceutical Co Ltd, Takeda Pharmaceuticals America Inc. - Blouin v. Takeda Pharmaceuticals America Inc et al	All
11/14/2013	11//14/2013	3589; 28	ANSWER to Plaintiffs' Complaint with Jury Demand. by Takeda Development Center Americas Inc, Eli Lilly & Co, Takeda California Inc, Takeda Pharmaceutical Co Ltd, Takeda Pharmaceuticals America Inc, Takeda Pharmaceuticals International Inc, Takeda Pharmaceuticals U S A Inc. - Estrade et al v. Takeda Pharmaceuticals U S A Inc et al	All
11/14/2013	11/14/2013	3590; 394	ORDER in case 6:11-md-02299-RFD-PJH; granting (390) Sealed Motion in case 6:12-cv-00064-RFD-PJH. Signed by Magistrate Judge Patrick J Hanna on 11/14/13. Having Considered the foregoing Motion for Leave of Court to File Reply in Support of Defendants Motion in Limine to Exclude Testimony of Helen Ge Under Seal; IT IS HEREBY ORDERED that the motion is granted and Defendants are given leave to file the Motion and Exhibits Under Seal. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/14/2013	11/14/2013	3591; 73	PROOF OF SERVICE of Proof of Service of Summons and Complaint upon Takeda Pharmaceuticals & Eli Lilly &	All

			Company - Moya v. Takeda Pharmaceuticals U S A Inc et al	
11/14/2013	11/14/2013	3592; 73	PROOF OF SERVICE of Proof of Service of Summons and Complaint upon Takeda Pharmaceuticals & Eli Lilly & Company - Carlson v. Takeda Pharmaceuticals U S A Inc et al	All
11/14/2013	11/14/2013	3593; 73	PROOF OF SERVICE of Proof of Service of Summons and Complaint upon Takeda Pharmaceuticals & Eli Lilly & Company - Labarca v. Takeda Pharmaceuticals U S A Inc et al	All
11/14/2013	11/14/2013	3594; 73	PROOF OF SERVICE of Proof of Service of Summons and Complaint upon Takeda Phamaceuticals & Eli Lilly & Company - Carter v. Takeda Pharmaceuticals U S A Inc et al	All
11/14/2013	11/14/2013	3595; 74	PROOF OF SERVICE of Proof of Service of Summons and Complaint upon Takeda Phamaceuticals & Eli Lilly & Company - Brubaker v. Takeda Pharmaceuticals U S A Inc et al	All
11/14/2013	11/14/2013	3596; 395	SEALED MOTION <i>Defendants' Motion to Exceed the Page Limit, From 10 pages to 15 Pages, and to File Their Reply in Support of Defendants' Motion for Summary Judgment Under Seal</i> by Eli Lilly & Co, Takeda California Inc, Takeda Development Center Americas Inc, Takeda Pharmaceutical Co Ltd, Takeda Pharmaceuticals International Inc, Takeda Pharmaceuticals L L C, Takeda Pharmaceuticals U S A Inc. Motions referred to Patrick J Hanna. (Attachments: # (1) Memorandum / Brief, # (2) Proposed order, # (3) Proposed pleading Reply in Support of Defendants' Motion for Summary Judgment. - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All
11/14/2013	11/14/2013	3597; 396	SEALED DOCUMENT: Reply in Support of Defendants' Motion in Limine to Exclude the Testimony of Helen GE by Eli Lilly & Co and Takeda Pharmaceuticals International Inc, et al re (3408 in 6:11-md-02299-RFD-PJH) <i>Defendants' Motion in Limine to Exclude the Testimony of Helen Ge.</i> (Attachments: # (1) Exhibit A) - Allen et al v. Takeda Pharmaceuticals North America Inc et al	All

DATED: November 15, 2013

Respectfully Submitted,

/s/ Sara J. Gourley

Sara J. Gourley
SIDLEY AUSTIN LLP
1 South Dearborn Street
Chicago, IL 60603
(312) 853-7000 (Phone)
(312) 853-7036 (Fax)
sknutson@sidley.com

Attorney for Defendants

CERTIFICATE OF SERVICE

I hereby certify that on November 15, 2013, I electronically filed the foregoing with the Clerk of Court by using the CM/ECF system, which will send a notice of electronic filing to Plaintiffs' Steering Committee, Lead Defense Counsel and Defendants' and Plaintiffs' designees. The designees will forward the NEFs to the appropriate attorneys as outlined by the Court's Case Management Order: Notice of Procedure [D.E. 3398].

/s/ Sara J. Gourley _____

Sara J. Gourley
SIDLEY AUSTIN LLP
1 South Dearborn Street
Chicago, IL 60603
(312) 853-7000 (Phone)
(312) 853-7036 (Fax)
sgourley@sidley.com